Treatment of ligneous conjunctivitis with platelet-rich plasma
- Conditions
- PlasminogenC11.187
- Registration Number
- RBR-83cj4wn
- Lead Sponsor
- niversidade Federal de São Paulo - UNIFESP/EPM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Patients diagnosed with ligneous conjunctivitis with chronic ocular involvement (more than 1 year of disease) who do not respond to clinical treatment and present recurrence of pseudomembranes after simple resection or after attempted clinical treatment. Age from 2 years. Availability to attend all study visits and adequately follow all post-operative guidelines and care. Understanding of the study, stages and follow-up, and agreement expressed by signing the consent form (by the patient or guardian) and assent form (when applicable). Stable clinical condition and no change in topical medications or systemic anti-inflammatory drugs in the 60 days prior to and during the study. Carry out a complete pre-operative assessment, including general and specific complementary exams as clinically indicated and pre-anesthetic assessment
Eye surgery in the last 6 months. Patients with a previous history of hypersensitivity to any of the products used to treat ligneous conjunctivitis included in this protocol. Pregnant or breastfeeding women. Active eye infection. History of herpetic keratitis. Use of contact lenses within 48 hours of the start of the study, or during the study. Glaucoma. Presence of any other serious ocular change that indicates the need to perform another ophthalmological procedure more urgently, such as retinal detachment or ocular perforation. Contraindication to carrying out the procedure by the anesthesiology team
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method